Pfizer/Medarex Antibody Collaboration Includes Cross-Licensing Of Melanoma Products
This article was originally published in The Pink Sheet Daily
Medarex expects cross-licensing anti-CTLA-4 products will enhance opportunities for future products by clearing up potential intellectual property issues. Pfizer will make up-front payments totaling $110 mil. to secure 50 antibody products over 10 years.
You may also be interested in...
The company plans a Subpart E filing as early as 2006 based on response rate data from the Phase III study, designed under a special protocol assessment with FDA. The immune-boosting MDX-010/MDX-1349 combination trial will start enrolling patients in September.
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
Sepracor's television ads for its sleep aid Lunesta create brand recognition better than other new prescription drug direct-to-consumer ads, according to an analysis performed by IAG Research